Publication date: Oct 03, 2019
Acthar Gel (repository corticotropin injection) eased flare-up symptoms in patients with multiple sclerosis (MS) experiencing relapses, top-line data from an observational registry study shows. The main goal of the study was to monitor the course of MS, document all relapses and the recovery process in a group of MS patients who had been treated with Acthar Gel for at least six months. The primary goal of the study was to assess the effect of Acthar Gel on symptoms associated with MS flare-ups after two months of treatment, based on the MSIS-29v1 scale (a tool that measures the impact of MS in physical and psychological aspects from a patient’s perspective). Top-line data from the study showed that patients treated with Acthar Gel not only reported marked improvements in their symptoms after two months of therapy, but also had a sustained response to the medication that was still apparent six months after enrolling in the study.
|Clinical Trials||Multiple sclerosis|
- #ECTRIMS2019 – Acthar Gel Seen as Cost-effective Late-line Treatment Option for MS Relapses
- Oral Ozanimod More Effective Than Avonex in Lowering Annual Relapses in MS Patients, Phase 3 Trial Finds
- #ECTRIMS2019 – 10-year Data Confirm Long-term Benefits of Biogen’s Tecfidera for RRMS